The evaluation the effect of nanocurcommin in people living with HIV

Evaluation of safety and efficiency of curcumin in the immune system and viral load of patient with HIV

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210216050373N4

Enrollment

100

Registered

2022-05-28

Start date

2022-07-06

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of nanocurrcomin in HIV treatment.

Interventions

Intervention 1: Control group: A group that only takes routine HIV medications. Intervention 2: Intervention group: A group that uses nanocurcumin in addition to basic drugs to treat HIV. This drug co

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: people with positive test ( PCR) people with positive test ( Elisa)

Exclusion criteria

Exclusion criteria: Patient with hepatitis B Patient with hepatitis C Pregnancy Breastfeeding Alcohol and Drug use Use of Growth Hormone (at least 30 days before the study) Use of Immunosuppressive drugs Use of Testosterone and Anabolic Steroids (at least 30 days before the study) Under Chemotherapy with Interferon or Radiotherapy Patients with Undetectable viral loads

Design outcomes

Primary

Measure	Time frame
Counting CD4 test. Timepoint: 30 days after first use. Method of measurement: with Flow cytometry instrument.;Viral load test. Timepoint: 30 days after first use. Method of measurement: ?????? PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedAhmad SeyedAlinaghi

Tehran University of Medical Sciences

s_a_alinaghi@yahoo.com+98 21 6658 1583

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026